Optimi To Supply Psilocybin For New Zealand's Mātai Medical Research Institute
Portfolio Pulse from Lara Goldstein
Optimi Health Corp. (OTCQX:OPTHF), a Canadian psychedelics pharmaceutical manufacturer, has entered into an agreement to supply natural psilocybin to New Zealand's Mātai Medical Research Institute for the Tū Wairua Project. This marks Optimi's first supply deal in New Zealand, contributing to its global expansion. The company will provide GMP Full Spectrum Natural Psilocybin extract for a pilot study aimed at evaluating psychedelic-assisted therapy for Māori patients. The study, set for mid-2024, will integrate Māori cultural practices and aims to inform future trials for methamphetamine use disorder among Māori patients.
April 09, 2024 | 7:26 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Optimi Health Corp. has signed a deal to supply psilocybin to New Zealand's Mātai Medical Research Institute for the Tū Wairua Project, marking its first supply agreement in New Zealand and a significant step in its global expansion.
The agreement with Mātai Medical Research Institute represents a significant milestone for Optimi Health Corp., indicating a strategic move into the New Zealand market and potentially boosting its global presence. This partnership could lead to increased visibility and credibility in the psychedelics pharmaceutical industry, likely positively impacting investor sentiment and the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100